Related Experiment Video
Updated: Jan 4, 2026
Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Energetic drain driving hypertrophic cardiomyopathy
Vasco Sequeira1, Edoardo Bertero1, Christoph Maack1
1Comprehensive Heart Failure Center (CHFC), University Clinic Würzburg, Germany.
Insights
Hypertrophic cardiomyopathy (HCM), a genetic heart condition, is often caused by sarcomeric protein mutations. Increased myofilament calcium sensitivity is a key factor driving HCM progression toward heart failure and sudden death.
Area of Science:
- Cardiology
- Genetics
- Molecular Biology
Background:
- Hypertrophic cardiomyopathy (HCM) is the most prevalent hereditary cardiomyopathy.
- It is primarily caused by mutations in genes encoding cardiac sarcomeric proteins.
- HCM presents with left ventricular hypertrophy not solely due to loading conditions, featuring diastolic dysfunction and arrhythmias.
Purpose of the Study:
- To review experimental and clinical evidence on the role of myofilament calcium sensitivity in HCM.
- To explore how increased myofilament calcium sensitivity contributes to disease progression.
Main Methods:
- Review of preclinical and clinical studies.
- Analysis of cellular and molecular mechanisms in HCM.
Main Results:
- Enhanced myofilament calcium (Ca2+) sensitivity is a critical factor in HCM pathophysiology.
- This increased sensitivity can arise directly from sarcomeric mutations or secondary alterations.
- Elevated myofilament Ca2+ sensitivity precedes cellular derangements leading to heart failure and sudden cardiac death.
Conclusions:
- Increased myofilament Ca2+ sensitivity is a central mechanism in HCM.
- Targeting myofilament Ca2+ sensitivity may offer therapeutic strategies for HCM.
- Understanding this pathway is crucial for managing HCM progression and preventing adverse outcomes.
Abstract:
Hypertrophic cardiomyopathy (HCM) is the most common form of hereditary cardiomyopathy and is mainly caused by mutations of genes encoding cardiac sarcomeric proteins. HCM is characterized by hypertrophy of the left ventricle, frequently involving the septum, that is not explained solely by loading conditions. HCM has a heterogeneous clinical profile, but diastolic dysfunction and ventricular arrhythmias represent two dominant features of the disease. Preclinical evidence indicates that the enhanced Calcium (Ca2+ ) sensitivity of the myofilaments plays a key role in the pathophysiology of HCM. Notably, this is not always a direct consequence of sarcomeric mutations, but can also result from secondary mutation-driven alterations. Here, we review experimental and clinical evidence indicating that increased myofilament Ca2+ sensitivity lies upstream of numerous cellular derangements which potentially contribute to the progression of HCM toward heart failure and sudden cardiac death.
